A cost-benefit analysis of genetic screening for susceptibility to occupational toxicants

Journal of Occupational and Environmental Medicine

Volumn 41, Issue 7, 1999, Pages 535-544

  Nicas, Mark ^a   Lomax, Geoffrey P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENE; BERYLLIUM; CYTOCHROME P450; HLA DP ANTIGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (QUINONE);

ARTICLE; BERYLLIOSIS; COST BENEFIT ANALYSIS; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; OCCUPATIONAL CANCER; OCCUPATIONAL EXPOSURE; OCCUPATIONAL TOXICOLOGY;

EID: 0033026698     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043764-199907000-00002     Document Type: Article

References (12)

1. Toniolo P. Application of Biomarkers in Cancer Epidemiology. Lyon, France: International Agency for Cancer Scientific Publications; 1997:7-16. No. 142.
2. Gonzalez FJ. Xenobiotic-metabolizing enzymes in biomarker research. In: Mendelshon ML, Peeters JP, Normandy MJ, eds. Biomarkers and Occupational Health: Progress and Perspectives. Washington, DC: Joseph Henry Press; 1995:238-256.
3. Saltini C. A genetic marker for chronic beryllium disease. In: Mendelsohn ML, Peeters, JP, Normandy MJ, eds. Biomarkers and Occupational Health: Progress and Perspectives. Washington, DC: Joseph Henry Press; 1995:293-303.
4. Rothstein M. Legal and ethical aspects of medical screening. In: Occupational Medicine: State of the Art Reviews, vol. 11, no. 1. Philadelphia: Hanley and Belfus, Inc.; 1996.
5. Khoury MJ, Wagener DK. Epidemiological evaluation of the use of genetics to improve the predictive value of disease risk factors. Am J Hum Genet. 1995;56: 835-844.
6. Holtzman NA. Medical and ethical issues in genetic screening - an academic view. Environ Health Perspect. 1996;104:987-990.
7. Kincaid D, Cheney W. Numerical Analysis, Mathematics of Scientific Computing. Pacific Grove, CA: Brooks/Cole Publishing Company; 1991.
8. 609C → T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res. 1997;57:2839-2842.
9. Rossman MD. Immunology of chronic beryllium disease. In: Mendelsohn ML, Peeters JP, Normandy MJ, eds. Biomarkers and Occupational Health: Progress and Perspectives. Washington, DC: Joseph Henry Press; 1995:304-312.
10. Richeldi L, Kreiss K, Mroz MM, et al. Interaction of genetic and exposure factors in the prevalence of berylliosis. Am J Ind Med. 1997;32:337-340.
11. Office of Technology Assessment. Prospects and problems for the economic evaluation of genetic testing. In: The Role of Genetic Testing in the Prevention of Occupational Disease. Washington DC: Congress of the United States, Office of Technology Assessment; 1983:151-160.
12. Boardman AE, Greenberg DH, Vining AR, Weimer DL. Cost Benefit Analysis: Concepts and Practice. Upper Saddle River, NJ: Prentice-Hall, Inc.; 1996.